SKI II

SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC50 values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation[1][2].

Product Specifications

CAS Number

[312636-16-1]

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; SphK; Wnt

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SKI-II.html

Purity

99.25

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1

Molecular Formula

C15H11ClN2OS

Molecular Weight

302.78

Precautions

H302

References & Citations

[1]Liu H, et al. SphK1 inhibitor SKI II inhibits the proliferation of human hepatoma HepG2 cells via the Wnt5A/β-catenin signaling pathway. Life Sci. 2016 Apr 15;151:23-9.|[2]Liu Y, et al. SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells. Oncol Lett. 2014 Jul;8 (1) :367-373.|[3]Potì F, et al. SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis. 2015 May;240 (1) :212-5.|[4]French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318 (2) :596-603.